Holding(s) in Company

Summary by AI BETAClose X

Premier Miton Group plc has acquired a significant stake in CRISM Therapeutics Corporation, now holding 9.471459% of the company's voting rights, totaling 7,500,000 shares. This notification, dated June 16, 2026, indicates a change in major shareholding, with the voting rights attached to shares being the sole form of holding, as no financial instruments are involved. The acquisition was completed through Premier Fund Managers Ltd, a subsidiary of Premier Miton Group plc.

Disclaimer*

UK 100

Latest directors dealings